Asthma

Midwest CEPAC

An estimated 22 million Americans have asthma, which causes the airways of the lungs to narrow or become blocked, making it hard to breathe. Among both young and old, asthma can have a significant impact on health and limit the ability to pursue many activities.

Interventions of Interest, 2018 review: Dupilumab (Dupixent®, Sanofi/Regeneron), omalizumab (Xolair®, Genentech/Novartis), mepolizumab (Nucala®, GlaxoSmithKline), reslizumab (Cinqair®, Teva), and benralizumab (Fasenra, AstraZeneca)

Intervention of interest, 2016 review: Mepolizumab (Nucala®, GlaxoSmithKline plc.)

 

ASSOCIATED MEETING & MATERIALS

Midwest CEPAC
November 29, 2018 10am-4pm CT

Hilton St. Louis Frontenac
1335 S Lindbergh Boulevard
St. Louis, MO 63131

Key Dates

Associated Materials

04/24/2018 – 05/10/2018
Open Input Period

05/15/2018

05/15/2018

05/15/2018 – 06/05/2018

06/13/2018

07/19/2018

08/09/2018

09/24/2018
Draft Voting Questions

09/24/2018
Draft Evidence Report

09/24/2018 – 10/22/2018
Public Comments

11/13/2018
Revised Voting Questions

11/13/2018
Evidence Report

11/13/2018
Response to Comments

11/29/2018
Meeting Agenda

12/20/2018
Final Evidence Report and Meeting Summary


ASSOCIATED MEETING & MATERIALS

CTAF
February 12, 2016 9:00AM-3:30PM

The California Endowment, Oakland, CA

The California Technology Assessment Forum (CTAF), a core program of the Institute for Clinical and Economic Review (ICER), held a public meeting in February 2016 to discuss a drug for patients with severe eosinophilic asthma. The asthma drug, mepolizumab (Nucala®, GlaxoSmithKline), is a once-monthly injectable monoclonal antibody against interleukin-5 (IL-5).

Key Dates

Associated Materials

10/13/2015

11/19/2015

12/21/2015

12/21/2015

12/21/2015 – 01/12/2016

Public comments received on the Draft Evidence Report.